Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort

Pharmacogenetics and Genomics

Volumn 24, Issue 7, 2014, Pages 367-369

  Gryn, Steven E ^a   Teft, Wendy A ^a   Kim, Richard B ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

drug interactions; drug monitoring; endoxifen; individualized medicine; phenytoin; tamoxifen

Indexed keywords

CLOBAZAM; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; DILTIAZEM; DOCETAXEL; ENDOXIFEN; EPIRUBICIN; FLUOROURACIL; HYDROCHLOROTHIAZIDE; PHENYTOIN; TAMOXIFEN; TRASTUZUMAB; VALPROIC ACID;

ADULT; ANTICONVULSANT THERAPY; ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CATHETER THROMBOSIS; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; LIQUID CHROMATOGRAPHY; MIDDLE AGED; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PSORIASIS; REDUCTION; TANDEM MASS SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; EPILEPSY; FEMALE; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; PHARMACOGENETICS; PHENYTOIN; TAMOXIFEN;

EID: 84902213323     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000051     Document Type: Article

References (10)

1. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011; 89: 718-725.
2. Gong IY, Teft WA, Ly J, Chen YH, Alicke B, Kim RB, et al. Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. Breast Cancer Res Treat 2013; 139: 61-69.
3. Jin Y, Desta Z, Stearns V,Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-39.
4. Kivisto KT, Villikka K, Nyman L, Anttila M, Neuvonen PJ. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998; 64: 648-654.
5. Ducharme J, Fried K, Shenouda G, Leyland-Jones B, Wainer IW. Tamoxifen metabolic patterns within a glioma patient population treated with high-dose tamoxifen. Br J Clin Pharmacol 1997; 43: 189-193.
6. Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Moghaddam-Helmantel IM, et al. Effects of CYP induction by rifampicin on tamoxifen exposure. Clin Pharmacol Ther 2012; 92: 62-67.
7. Teft WA, Gong IY, Dingle B, Potvin K, Younus J, Vandenberg TA, et al. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Res Treat 2013; 139: 95-105.
8. Kohle C, Bock KW. Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem Pharmacol 2009; 77: 689-699.
9. Teft WA, Mansell SE, Kim RB. Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos 2011; 39: 558-562.
10. Boruban MC, Yasar U, Babaoglu MO, Sencan O, Bozkurt A. Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother 2006; 18: 421-424.